Clinical trial of the gneric product UNILAT following its efficiency and safety in glaucoma and intraocular hypertension;Klinické sledovanie účinnosti a bezpečnosti generického produktu UNILAT v terapii glaukómu a vnútroočnej hypertenzie

Ceska a Slovenska Oftalmologie

Volumn 66, Issue 6, 2010, Pages 258-261

  Strmen P ^a   Jancus V ^b   Okkelova J ^b   Tvrdonova M ^b  

^a LFUK   (Slovakia)

^b UNIMED PHARMA Spol S R o   (Slovakia)

Author keywords

Efficacy; Glaucoma; Latanoprost; Safety; UNILAT

Indexed keywords

ANTIHYPERTENSIVE AGENT; LATANOPROST; PROSTAGLANDIN F;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PHASE 3 CLINICAL TRIAL;

ANTIHYPERTENSIVE AGENTS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC;

EID: 79951518892     PISSN: 12119059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Aim A., Widengard I., Kjellgren D., et al.: Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. BMC Ophthalmology, 1995, 79:12-16.
2. Guideline on the choice of the non-inferiority margin. London, 2005; EMEA/CPMP/EWP/2158/99.
3. http://www.zelenyzakal.sk/zeleny-zakal/glaukom/.
4. Perry CM., McGavin J.K., Culy Ch.R. et al.: Latanoprost. An Update of its Use in Glaucoma Hypertension. Drugs & aging, 2003, 20: 597-630.
5. Points to consider on switching between superiority and noninferiority. London 2000; CPMP/EWP/482/99.
6. Resul B., Stjernschantz J., Kiyo N., et al.: Phenyl-Substituted Prostaglandins: Potent and selective antiglaucoma agents. J Med Chem, 1993, 36: 243-248. (Pubitemid 23060092)
7. Stjernschantz J., Resul B.: Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs of the future, 1992, 17: 691-704.